Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Biotech
Parabilis ups planned IPO haul to record-setting $637M
Once known as FogPharma, Parabilis plans to offer 33,333,334 shares of common stock priced between $17 and $19 apiece.
Darren Incorvaia
Jun 9, 2026 10:22am
Lilly licenses AlzeCure Alzheimer’s asset for $1B biobucks
Jun 9, 2026 10:16am
How AI is reshaping biopharma decision-making
Brought to you by
Clarivate
ADA: AZ’s oral GLP-1 shows ‘competitive efficacy’ in phase 2
Jun 9, 2026 9:48am
Managing complexity across biopharma modalities
Brought to you by
SK Pharmteco
Bial bails after Parkinson’s fail, axing asset over phase 2 miss
Jun 9, 2026 5:22am
